Stock Groups

Regeneron says COVID-19 drug could be less effective against Omicron variant -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: A building at Regeneron Pharmaceuticals’ Westchester campus is adorned with the Regeneron Pharmaceuticals brand logo. It was erected in Tarrytown New York on September 17, 2020. REUTERS/Brendan McDermid

(Reuters] -Regeneron Pharmaceuticals Inc claimed Tuesday that previous analyses had suggested that the COVID-19 antibodies cocktail of Regeneron Pharmaceuticals Inc and others could have decreased activity against Omicron Coronavirus variant.

Analysis of the Omicron mutations revealed that “there may be decreased neutralization activity for both vaccine-induced immunity and monoclonal immune system conveyed immunity”.

The company stated that further analyses are underway and added that no data was available to test Omicron for resistance to monoclonal antibody or vaccine immunity.

These comments are available. Moderna (NASDAQ) Inc’s chief Executive Officer, said that COVID-19 vaccines were unlikely to prove as effective against Omicron as they had been in the past.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]